Nimodipine-d7

• UNSPSC Description:

  Nimodipine-d7 is the deuterium labeled Nimodipine. Nimodipine (BAY-e 9736) is an orally active, well-tolerated and light-sensitive dihydropyridine calcium antagonist. Nimodipine can be used for the research of cerebrovascular disorders[1].

• Target Antigen:

  Autophagy; Calcium Channel; Isotope-Labeled Compounds

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Autophagy;Membrane Transporter/Ion Channel;Neuronal Signaling;Others

• Field of Research:

  Cardiovascular Disease; Cancer

• Purity:

  99.35

• Solubility:

  DMSO : 100 mg/mL (ultrasonic;warming)

• Smiles:

  COCCOC(C1=C(C)NC(C)=C(C(OC(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])=O)C1C2=CC(N(=O)=O)=CC=C2)=O

• Molecular Weight:

  425.48

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Langley, M.S., et al. Nimodipine. Drugs 37, 669–699 (1989).|[3] Marbacher S, et al. Prevention of delayed cerebral vasospasm by continuous intrathecal infusion of glyceroltrinitrate and nimodipine in the rabbit model in vivo. Intensive Care Med. 2008;34(5):932-938.|[4]Honn KV, et al. Inhibition of tumor cell-platelet interactions and tumor metastasis by the calcium channel blocker, nimodipine. Clin Exp Metastasis. 1984;2(1):61-72.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1246815-36-0